Limits...
Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy

View Article: PubMed Central - PubMed

ABSTRACT

Liver stiffness (LS) assessed using transient elastography (TE) can assess the risk of developing hepatocellular carcinoma (HCC). We evaluated whether TE, when compared with histological data as a reference standard, can predict the risk of HCC development in chronic hepatitis B (CHB) patients starting antiviral therapy.

Observational cohort database of 381 patients with CHB who underwent liver biopsy (LB) and TE were reviewed. All patients underwent surveillance for HCC development using ultrasonography and alpha-fetoprotein.

During the median follow-up period of 48.1 (interquartile range 30.3–69.3) months, HCC developed in 34 (8.9%) patients. In patients with HCC development, age, proportion of diabetes mellitus, histological fibrosis stage, and LS value were significantly higher than those in patients without (all P <0.05). The cumulative incidence rates of HCC increased significantly in association with elevated LS value in 3 stratified groups (LS value <8, 8–13, and >13 kPa; log-rank test, P <0.001), and with higher histological fibrosis stage in 3 stratified groups (F0–2, F3, and F4; log-rank test, P <0.001). On multivariate analysis, along with age, LS value was an independent predictor of HCC development (hazard ratio 1.041, P <0.001), whereas histological staging was not (P >0.05).

TE predicted HCC development independently in patients with CHB starting antiviral therapy. However, further investigation is needed to determine whether the current surveillance strategy can be optimized based on the LS value at the time of starting antiviral therapy.

No MeSH data available.


Related in: MedlinePlus

The cumulative incidence rates of HCC (A) and LRE (B) (Kaplan–Meier plot). The cumulative incidence rates of HCC at 3, 5, and 7 years were 6.5%, 11.2%, and 11.9%, respectively, with an annual incidence of 22 per 1000 person-years. The cumulative incidence rates of LREs at 3, 5, and 7 years were 7.0%, 11.7%, and 12.5%, respectively, with an annual incidence of 23 per 1000 person-years. HCC = hepatocellular carcinoma; LRE = liver-related event.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998368&req=5

Figure 1: The cumulative incidence rates of HCC (A) and LRE (B) (Kaplan–Meier plot). The cumulative incidence rates of HCC at 3, 5, and 7 years were 6.5%, 11.2%, and 11.9%, respectively, with an annual incidence of 22 per 1000 person-years. The cumulative incidence rates of LREs at 3, 5, and 7 years were 7.0%, 11.7%, and 12.5%, respectively, with an annual incidence of 23 per 1000 person-years. HCC = hepatocellular carcinoma; LRE = liver-related event.

Mentions: During a median follow-up period of 48.1 (IQR 30.3–69.3) months, 34 (8.9%) patients experienced HCC development. Furthermore, 36 (9.4%) patients experienced LRE development (31 HCCs and 5 hepatic decompensations as the first event). The cumulative incidence rates of HCC at 3, 5, and 7 years were 6.5%, 11.2%, and 11.9%, respectively, with an annual incidence of 22 per 1000 person-years (Figure 1A). The cumulative incidence rates of LRE at 3, 5, and 7 years were 7.0%, 11.7%, 12.5%, respectively, with an annual incidence of 23 per 1000 person-years (Figure 1B).


Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy
The cumulative incidence rates of HCC (A) and LRE (B) (Kaplan–Meier plot). The cumulative incidence rates of HCC at 3, 5, and 7 years were 6.5%, 11.2%, and 11.9%, respectively, with an annual incidence of 22 per 1000 person-years. The cumulative incidence rates of LREs at 3, 5, and 7 years were 7.0%, 11.7%, and 12.5%, respectively, with an annual incidence of 23 per 1000 person-years. HCC = hepatocellular carcinoma; LRE = liver-related event.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998368&req=5

Figure 1: The cumulative incidence rates of HCC (A) and LRE (B) (Kaplan–Meier plot). The cumulative incidence rates of HCC at 3, 5, and 7 years were 6.5%, 11.2%, and 11.9%, respectively, with an annual incidence of 22 per 1000 person-years. The cumulative incidence rates of LREs at 3, 5, and 7 years were 7.0%, 11.7%, and 12.5%, respectively, with an annual incidence of 23 per 1000 person-years. HCC = hepatocellular carcinoma; LRE = liver-related event.
Mentions: During a median follow-up period of 48.1 (IQR 30.3–69.3) months, 34 (8.9%) patients experienced HCC development. Furthermore, 36 (9.4%) patients experienced LRE development (31 HCCs and 5 hepatic decompensations as the first event). The cumulative incidence rates of HCC at 3, 5, and 7 years were 6.5%, 11.2%, and 11.9%, respectively, with an annual incidence of 22 per 1000 person-years (Figure 1A). The cumulative incidence rates of LRE at 3, 5, and 7 years were 7.0%, 11.7%, 12.5%, respectively, with an annual incidence of 23 per 1000 person-years (Figure 1B).

View Article: PubMed Central - PubMed

ABSTRACT

Liver stiffness (LS) assessed using transient elastography (TE) can assess the risk of developing hepatocellular carcinoma (HCC). We evaluated whether TE, when compared with histological data as a reference standard, can predict the risk of HCC development in chronic hepatitis B (CHB) patients starting antiviral therapy.

Observational cohort database of 381 patients with CHB who underwent liver biopsy (LB) and TE were reviewed. All patients underwent surveillance for HCC development using ultrasonography and alpha-fetoprotein.

During the median follow-up period of 48.1 (interquartile range 30.3–69.3) months, HCC developed in 34 (8.9%) patients. In patients with HCC development, age, proportion of diabetes mellitus, histological fibrosis stage, and LS value were significantly higher than those in patients without (all P <0.05). The cumulative incidence rates of HCC increased significantly in association with elevated LS value in 3 stratified groups (LS value <8, 8–13, and >13 kPa; log-rank test, P <0.001), and with higher histological fibrosis stage in 3 stratified groups (F0–2, F3, and F4; log-rank test, P <0.001). On multivariate analysis, along with age, LS value was an independent predictor of HCC development (hazard ratio 1.041, P <0.001), whereas histological staging was not (P >0.05).

TE predicted HCC development independently in patients with CHB starting antiviral therapy. However, further investigation is needed to determine whether the current surveillance strategy can be optimized based on the LS value at the time of starting antiviral therapy.

No MeSH data available.


Related in: MedlinePlus